2024-2032 年旅游疫苗市场报告（按成分、疾病和地区）

2023年全球旅行疫苗市场规模达到40亿美元。展望未来， IMARC Group预计到2032年市场规模将达到94亿美元，2024-2032年复合年增长率（CAGR）为9.6%。由于对异国情调和不走寻常路的旅行体验的需求不断增长、政府作为公共卫生计划的一部分向公民提供免费旅行疫苗的倡议以及不断变化的疾病模式和新出现的威胁，该市场正在经历稳定增长。

旅行疫苗市场分析：

市场成长与规模：市场正在强劲成长，这可归因于国际旅行活动的增加。此外，大众对旅行相关疾病的认识不断提高，也推动了市场的成长。

技术进步：疫苗开发方面的创新，例如引入更方便、更有效的配方，确保为旅行者提供更好的保护。

产业应用：旅行疫苗对于休閒和商务旅客都至关重要，因为它们可以预防各种疾病。

地理趋势：北美由于高度重视旅行期间的健康和安全而引领市场。然而，在多样化的目的地和大量国际游客的推动下，欧洲正在成为一个快速成长的市场。

竞争格局：市场主要参与者积极参与策略倡议。他们正在投资研发（R＆D）活动，以扩大其疫苗组合，解决新出现的与旅行相关的健康风险，并提高疫苗的现有功效。

挑战与机会：虽然市场面临疫苗犹豫和监管障碍等挑战，但它也遇到了扩大疫苗可及性和为特定地区量身定制疫苗解决方案的机会。

未来展望：随着疫苗生产方面持续的研发（R＆D）活动，旅行疫苗市场的未来看起来充满希望。此外，采用数位健康解决方案进行旅行前咨询预计将推动市场的成长。

旅行疫苗市场趋势：

国际旅行不断增加

世界各地大众国际旅行的增加正在支持市场的成长。随着全球化和旅行便利性的不断增强，世界各地感染传染病的风险正在上升。旅行者正在冒险前往医疗保健标准和疾病流行率各不相同的目的地，因此接种疫苗成为至关重要的预防措施。休閒旅行、商务旅行和国际学生出国留学的成长进一步推动了这一趋势。此外，对异国情调和人迹罕至的旅行体验的渴望正在引导人们探索具有独特健康风险的地区，这强调了对专门疫苗的需求。人们对旅行时健康预防措施的认识不断增强，凸显了疫苗对国际旅客的重要性，这提供了良好的市场前景。

政府措施和法规

政府措施和法规在推动市场方面发挥关键作用。许多国家正在认识到维护公共卫生和防止疾病透过国际旅行传播的重要性。因此，一些国家的管理机构正在实施有关旅行疫苗接种的严格法规和建议。这些法规通常要求进出其边境的旅行者接种某些疫苗，特别是对于具有已知疾病风险的目的地。世界卫生组织 (WHO) 的《国际卫生条例》(IHR) 要求前往某些国家的旅客提供黄热病疫苗接种证明。此外，作为公共卫生计划的一部分，一些政府为其公民提供补贴或免费旅行疫苗接种。这些法规和措施不仅为旅行者提出了法律要求，也提高了人们对旅行疫苗必要性的认识，从而推动了市场需求。

全球疾病爆发和流行病

全球疾病爆发和流行病对推动市场产生深远影响。这些事件鼓舞了旅客和政府，并凸显了与国际旅行相关的潜在健康风险。为了应对此类疫情，对能够预防某些地区流行的特定传染病的疫苗的需求不断增加。疾病爆发和流行病导致疫苗的开发和分发，以减轻病毒的传播并促进安全旅行。旅行者越来越意识到需要接种疫苗来保护自己和他人，导致更多人采用旅行疫苗。各国政府和国际卫生组织也强调疫苗作为预防和控制疫情的关键工具的重要性，并鼓励旅客在踏上旅程之前接种疫苗。

不断变化的疾病模式和新出现的威胁

疾病模式的动态性质和新传染病威胁的出现正在加强市场的成长。传染病并不是一成不变的，它们会进化、变异并传播到新的地区。这种不断变化的情况需要持续的疫苗研发 (R&D) 活动来对抗不断变化的病原体。近年来，寨卡病毒和伊波拉病毒等疾病日益成为旅客的重大担忧，促使特定疫苗的开发来应对这些威胁。这种对疾病模式变化的认识，以及获取资讯的便利性，正在鼓励人们在踏上旅程之前透过疫苗接种寻求保护。

目录

第一章：前言

第 2 章：范围与方法

• 研究目的
• 利害关係人
• 资料来源
  • 主要资源
  • 二手资料
• 市场预测
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第 3 章：执行摘要

第 4 章：简介

• 概述
• 主要行业趋势

第 5 章：全球旅行疫苗市场

• 市场概况
• 市场业绩
• COVID-19 的影响
• 市场区隔：依构成
• 市场区隔：依疾病分类
• 市场区隔：按地区
• 市场预测

第 6 章：市场区隔：依构成

• 单一疫苗
  • 市场走向
  • 市场预测
• 联合疫苗
  • 市场走向
  • 市场预测

第 7 章：市场区隔：依疾病分类

• 甲型肝炎
  • 市场走向
  • 市场预测
• DPT
  • 市场走向
  • 市场预测
• 黄热病
  • 市场走向
  • 市场预测
• 伤寒
  • 市场走向
  • 市场预测
• B型肝炎
  • 市场走向
  • 市场预测
• 麻疹和腮腺炎
  • 市场走向
  • 市场预测
• 狂犬病
  • 市场走向
  • 市场预测
• 脑膜炎球菌
  • 市场走向
  • 市场预测
• 水痘
  • 市场走向
  • 市场预测
• 日本脑炎
  • 市场走向
  • 市场预测
• 其他的
  • 市场走向
  • 市场预测

第 8 章：市场区隔：按地区

• 北美洲
  • 市场走向
  • 市场预测
• 欧洲
  • 市场走向
  • 市场预测
• 亚太地区
  • 市场走向
  • 市场预测
• 中东和非洲
  • 市场走向
  • 市场预测
• 拉丁美洲
  • 市场走向
  • 市场预测

第 9 章：全球旅行疫苗产业：SWOT 分析

• 概述
• 优势
• 弱点
• 机会
• 威胁

第 10 章：全球旅行疫苗产业：价值链分析

• 探索阶段
• 临床前和临床开发
• 监管批准
• 製造业
• 行销与分销

第 11 章：全球旅行疫苗产业：波特五力分析

• 概述
• 买家的议价能力
• 供应商的议价能力
• 竞争程度
• 新进入者的威胁
• 替代品的威胁

第 12 章：全球旅行疫苗产业：价格分析

第 13 章：旅行疫苗生产流程

• 产品概述
• 原料要求
• 製造流程
• 关键成功因素与风险因素

第14章：竞争格局

• 市场结构
• 关键参与者
• 关键参与者简介
  • GlaxoSmithKline Pharmaceuticals Limited
  • Sanofi Pasteur
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • ALK-Abello A/S
  • Bavarian Nordic A/S
  • Crucell (Subsidiary of Johnson & Johnson)
  • CSL Limited
  • AstraZeneca PLC
  • Altimmune, Inc.
  • Abbott Laboratories
  • Hoffmann-La Roche, Inc.

Abstract

The global travel vaccines market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.6% during 2024-2032. The market is experiencing steady growth driven by the escalating demand for exotic and off-the-beaten-path travel experiences, government initiatives to provide free travel vaccinations to their citizens as part of public health programs, and changing disease patterns and emerging threats.

Travel Vaccines Market Analysis:

Market Growth and Size: The market is witnessing strong growth, which can be attributed to increasing international travel activities. In addition, the rising awareness among the masses about travel-related diseases is bolstering the market growth.

Technological Advancements: Innovations in vaccine development, such as the introduction of more convenient and effective formulations, is ensuring better protection for travelers.

Industry Applications: Travel vaccines are crucial for both leisure and business travelers, as they offer protection against various diseases.

Geographical Trends: North America leads the market, on account of its strong emphasis on health and safety during travel. However, Europe is emerging as a fast-growing market, driven by its diverse range of destinations and a large number of international travelers.

Competitive Landscape: Key players in the market are actively engaged in strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks, and enhancing existing efficacy of vaccines.

Challenges and Opportunities: While the market faces challenges, such as vaccine hesitancy and regulatory hurdles, it also encounters opportunities in expanding vaccine accessibility and tailored vaccine solutions for specific regions.

Future Outlook: The future of the travel vaccines market looks promising, with ongoing research and development (R&D) activities in vaccine production. Moreover, the adoption of digital health solutions for pre-travel consultations is expected to propel the growth of the market.

Travel Vaccines Market Trends:

Rising international travel

The increasing international travel among the masses around the world is supporting the growth of the market. As globalization and accessibility to travel are growing, the risk of exposure to infectious diseases in various parts of the world is rising. Travelers are venturing to destinations with varying healthcare standards and disease prevalence, making vaccinations a crucial precaution. This trend is further bolstered by the growth of leisure travel, business travel, and international students studying abroad. Moreover, the desire for exotic and off-the-beaten-path travel experiences is leading individuals to explore regions with unique health risks, emphasizing the need for specialized vaccines. The growing awareness among individuals about health precautions while traveling is underscoring the importance of vaccines for international travelers, which is offering a favorable market outlook.

Government initiatives and regulations

Government initiatives and regulations play a pivotal role in driving the market. Many countries are recognizing the importance of safeguarding public health and preventing the spread of diseases through international travel. As a result, governing agencies of several countries are implementing stringent regulations and recommendations regarding travel vaccinations. These regulations often mandate certain vaccinations for travelers entering or exiting their borders, especially for destinations with known disease risks. The International Health Regulations (IHR) by the World Health Organization (WHO) require proof of yellow fever vaccination for travelers visiting certain countries. Additionally, some governments offer subsidized or free travel vaccinations to their citizens as part of public health programs. These regulations and initiatives not only create a legal requirement for travelers but also raise awareness about the necessity of travel vaccines, driving demand in the market.

Global disease outbreaks and pandemics

Global disease outbreaks and pandemics have a profound impact on driving the market. These events are encouraging travelers and governments, highlighting the potential health risks associated with international travel. In response to such outbreaks, there is an escalating demand for vaccines that can protect against specific infectious diseases prevalent in certain regions. Disease outbreaks and pandemics are leading to the development and distribution of vaccines to mitigate the spread of the virus and facilitate safe travel. Travelers are becoming more conscious about the need for vaccinations to protect themselves and others, leading to greater adoption of travel vaccines. Governments and international health organizations also emphasize the importance of vaccines as a key tool in preventing and controlling outbreaks, encouraging travelers to be vaccinated before embarking on their journeys.

Changing disease patterns and emerging threats

The dynamic nature of disease patterns and the emergence of new infectious threats are strengthening the growth of the market. Infectious diseases are not static, they evolve, mutate, and spread to new regions. This ever-changing landscape necessitates ongoing research and development (R&D) activities of vaccines to combat evolving pathogens. Diseases like Zika virus and Ebola are emerging as significant concerns for travelers in recent years, prompting the development of specific vaccines to address these threats. This awareness of changing disease patterns, along with the ease of accessing information, is encouraging individuals to seek protection through vaccinations before embarking on their journeys.

Travel Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on composition and disease.

Breakup by Composition:

Mono Vaccines

Combination Vaccines

Combination vaccines account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the composition. This includes mono vaccines and combination vaccines. According to the report, combination vaccines represented the largest segment.

Combination vaccines offer the convenience of protecting against multiple diseases with a single injection. Popular combination vaccines include those that guard against hepatitis A and B, as well as typhoid. The primary advantage of combination vaccines is their efficiency in providing comprehensive protection, simplifying the vaccination process for travelers. This convenience is especially appealing to individuals who plan to visit regions with multiple disease risks, reducing the number of shots required. The combination vaccines segment is growing due to increased demand for streamlined vaccination regimens and improved compliance among travelers seeking a one-shot solution for their health needs.

Mono vaccines consist of individual vaccines targeting specific diseases. These vaccines are designed to provide protection against a single infectious agent, such as hepatitis A, hepatitis B, or typhoid. Mono vaccines are often recommended when travelers are visiting regions with a particularly high risk of one specific disease. They offer the advantage of targeted protection, allowing travelers to customize their vaccination regimen based on their destination and individual health needs.

Breakup by Disease:

Hepatitis A

DPT

Yellow Fever

Typhoid

Hepatitis B

Measles and Mumps

Rabies

Meningococcal

Varicella

Japanese Encephalitis

Others

Hepatitis A represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the disease. This includes hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, Japanese encephalitis, and others. According to the report, hepatitis A represented the largest segment.

Hepatitis A is a highly contagious viral infection that can be contracted through contaminated food or water, making it a significant concern for travelers. This segment includes vaccines that provide immunity against the hepatitis A virus. Due to its prevalence in many travel destinations, hepatitis A vaccination is recommended for individuals traveling to regions with inadequate sanitation and hygiene standards. The prominence of hepatitis A in the market reflects the widespread recognition of its risk and the importance of vaccination for the health and safety of travelers.

DPT vaccines, which protect against diphtheria, pertussis (whooping cough), and tetanus, are another important segment in the travel vaccines market. While these diseases are not exclusive to travel-related risks, they are included in some international vaccination recommendations. Tetanus can be a concern if travelers are exposed to contaminated wounds during their journeys. Therefore, DPT vaccines are essential for ensuring comprehensive protection against these preventable diseases, even when traveling.

Yellow fever vaccines target the prevention of yellow fever, a mosquito-borne viral disease prevalent in certain tropical regions. Travelers visiting countries in Africa and South America where yellow fever is endemic often require proof of vaccination for entry. The yellow fever segment in the travel vaccines market serves travelers who plan to explore these high-risk areas and need to adhere to international health regulations.

Typhoid vaccines are essential for travelers heading to regions with a higher risk of typhoid fever, often linked to contaminated food and water sources. These vaccines protect against Salmonella typhi, the bacterium responsible for typhoid fever. The typhoid segment addresses the specific health needs of travelers venturing to areas with suboptimal sanitation and hygiene conditions.

Hepatitis B vaccines are important for travelers who may engage in activities that carry an elevated risk of exposure to the hepatitis B virus, such as unprotected sexual contact or medical procedures involving needles. While hepatitis B is not exclusive to travel, these vaccines cater to the needs of individuals seeking protection against this virus while away from their home country.

Breakup by Region:

Asia Pacific

North America

Europe

Middle East and Africa

Latin America

North America leads the market, accounting for the largest travel vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share due to the high level of outbound international travel from the United States and Canada. The region has a strong emphasis on health and safety during travel, and travelers are well-informed about the importance of vaccinations. Additionally, government recommendations and regulations, including those set by the Centers for Disease Control and Prevention (CDC) in the United States, play a significant role in promoting the uptake of travel vaccines. North America also benefits from a well-established healthcare infrastructure and a robust pharmaceutical industry, making travel vaccines readily accessible to the population.

Europe is another substantial market for travel vaccines. With its diverse range of destinations and a large number of international travelers, European countries have a strong demand for travel vaccinations. The European Union is establishing guidelines for travelers, recommending vaccinations based on destination and health history. European travelers tend to be proactive in seeking pre-travel healthcare advice, contributing to the growth of the market in the region.

The Asia Pacific region is experiencing rapid growth in the market due to a rise in outbound tourism and business travel. As economies in the region are expanding, more individuals have the means and desire to explore international destinations. This is resulting in a heightened awareness of travel-related health risks, catalyzing the demand for travel vaccines. Moreover, some countries are becoming popular tourist destinations, leading to an increase in inbound travelers who also require vaccinations.

The Middle East and Africa region also contribute to the market. This segment is driven by both outbound tourism and inbound travelers, as the region hosts various cultural, religious, and business events. Vaccinations are often mandated for individuals traveling to Mecca for Hajj or Umrah, further propelling the market growth. In addition, the presence of diseases like yellow fever and malaria underscores the importance of vaccinations for travelers.

Latin America is another growing market for travel vaccines, driven by increasing outbound travel from countries like Brazil and Mexico. Travelers from these regions often explore destinations within South America, North America, and Europe, necessitating vaccinations for disease prevention.

Leading Key Players in the Travel Vaccines Industry:

Key players in the market are actively engaged in several strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks and enhancing existing efficacy of vaccines. These companies are also focusing on increasing their global distribution networks to ensure accessibility to travel vaccines in diverse regions. Furthermore, they collaborate with healthcare providers, government agencies, and international health organizations to promote vaccination awareness and education among travelers. Additionally, pharmaceutical firms are exploring innovative vaccine delivery methods, such as oral or patch-based vaccines, to improve convenience and compliance for travelers. Overall, key players are dedicated to advancing the field of travel vaccines to meet the evolving needs of global travelers effectively.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

GlaxoSmithKline Pharmaceuticals Limited

Sanofi Pasteur

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

ALK-Abello A/S

Bavarian Nordic A/S

Crucell (Subsidiary of Johnson & Johnson)

CSL Limited

AstraZeneca PLC

Altimmune, Inc.

Abbott Laboratories

Hoffmann-La Roche, Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

March 31, 2021: Sanofi Pasteur announced a huge investment in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment in a new facility will provide additional antigen and filling capacity for Sanofi's Fluzone® High-Dose Quadrivalent influenza vaccine, helping to increase supply availability in Canada, the United States and Europe.

January 5, 2022: Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

June 1, 2021: Merck & Co., Inc. announced that Vaxelis vaccine, developed as a part of a U.S. based partnership between Merck and Sanofi Pasteur is now available in the U.S. VAXELIS is the first and only hexavalent (six-in-one) combination vaccine available in the U.S. indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B.

Key Questions Answered in This Report

• 1. What is the size of the global travel vaccines market in 2023?
• 2. What is the expected growth rate of the global travel vaccines market during 2024-2032?
• 3. What are the key factors driving the global travel vaccines market?
• 4. What has been the impact of COVID-19 on the global travel vaccines market?
• 5. What is the breakup of the global travel vaccines market based on the composition?
• 6. What is the breakup of the global travel vaccines market based on the disease?
• 7. What are the key regions in the global travel vaccines market?
• 8. Who are the key companies/players in the global travel vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Travel Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Composition
• 5.5 Market Breakup by Disease
• 5.6 Market Breakup by Region
• 5.7 Market Forecast

6 Market Breakup by Composition

• 6.1 Mono Vaccines
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Combination Vaccines
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Disease

• 7.1 Hepatitis A
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 DPT
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Yellow Fever
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Typhoid
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Hepatitis B
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Measles and Mumps
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Rabies
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast
• 7.8 Meningococcal
  • 7.8.1 Market Trends
  • 7.8.2 Market Forecast
• 7.9 Varicella
  • 7.9.1 Market Trends
  • 7.9.2 Market Forecast
• 7.10 Japanese Encephalitis
  • 7.10.1 Market Trends
  • 7.10.2 Market Forecast
• 7.11 Others
  • 7.11.1 Market Trends
  • 7.12.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Global Travel Vaccines Industry: SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Global Travel Vaccines Industry: Value Chain Analysis

• 10.1 Exploratory Stage
• 10.2 Preclinical and Clinical Development
• 10.3 Regulatory Approval
• 10.4 Manufacturing
• 10.5 Marketing and Distribution

11 Global Travel Vaccines Industry: Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Global Travel Vaccines Industry: Price Analysis

13 Travel Vaccines Manufacturing Process

• 13.1 Product Overview
• 13.2 Raw Material Requirements
• 13.3 Manufacturing Process
• 13.4 Key Success and Risk Factors

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 GlaxoSmithKline Pharmaceuticals Limited
  • 14.3.2 Sanofi Pasteur
  • 14.3.3 Merck & Co., Inc.
  • 14.3.4 Novartis AG
  • 14.3.5 Pfizer Inc.
  • 14.3.6 ALK-Abello A/S
  • 14.3.7 Bavarian Nordic A/S
  • 14.3.8 Crucell (Subsidiary of Johnson & Johnson)
  • 14.3.9 CSL Limited
  • 14.3.10 AstraZeneca PLC
  • 14.3.11 Altimmune, Inc.
  • 14.3.12 Abbott Laboratories
  • 14.3.13 Hoffmann-La Roche, Inc.

List of Figures

• Figure 1: Global: Travel Vaccines Market: Major Drivers and Challenges
• Figure 2: Global: Travel Vaccines Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Travel Vaccines Market: Breakup by Composition (in %), 2023
• Figure 4: Global: Travel Vaccines Market: Breakup by Disease (in %), 2023
• Figure 5: Global: Travel Vaccines Market: Breakup by Region (in %), 2023
• Figure 6: Global: Travel Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 7: Global: Travel Vaccines Industry: SWOT Analysis
• Figure 8: Global: Travel Vaccines Industry: Value Chain Analysis
• Figure 9: Global: Travel Vaccines Industry: Porter's Five Forces Analysis
• Figure 10: Global: Travel Vaccines (Mono Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: Travel Vaccines (Mono Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: Travel Vaccines (Combination Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: Travel Vaccines (Combination Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: Travel Vaccines (Hepatitis A) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: Travel Vaccines (Hepatitis A) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: Travel Vaccines (DPT) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: Travel Vaccines (DPT) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: Travel Vaccines (Yellow Fever) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: Travel Vaccines (Yellow Fever) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: Travel Vaccines (Typhoid) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: Travel Vaccines (Typhoid) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: Travel Vaccines (Hepatitis B) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: Travel Vaccines (Hepatitis B) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: Travel Vaccines (Measles and Mumps) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Global: Travel Vaccines (Measles and Mumps) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Global: Travel Vaccines (Rabies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Global: Travel Vaccines (Rabies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: Global: Travel Vaccines (Meningococcal) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: Global: Travel Vaccines (Meningococcal) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 30: Global: Travel Vaccines (Varicella) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 31: Global: Travel Vaccines (Varicella) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 32: Global: Travel Vaccines (Japanese Encephalitis) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: Global: Travel Vaccines (Japanese Encephalitis) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Global: Travel Vaccines (Others) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Global: Travel Vaccines (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: North America: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: North America: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Europe: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Europe: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: Asia Pacific: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: Asia Pacific: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: Middle East and Africa: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 43: Middle East and Africa: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 44: Latin America: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 45: Latin America: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 46: Travel Vaccines Manufacturing: Process Flow

List of Tables

• Table 1: Global: Travel Vaccines Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Travel Vaccines Market Forecast: Breakup by Composition (in Million US$), 2024-2032
• Table 3: Global: Travel Vaccines Market Forecast: Breakup by Disease (in Million US$), 2024-2032
• Table 4: Global: Travel Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Travel Vaccines: Raw Material Requirements
• Table 6: Global: Travel Vaccines Market Structure
• Table 7: Global: Travel Vaccines Market: Key Players